A partial length recombinant HOXA9 protein (amino acids 63-272) was used as the immunogen for this antibody.
Alternative Names:
HOXA9||HOX1G
HOXA9 is a well-studied member of the HOXA cluster, and it plays a significant role in both normal hematopoiesis and leukemogenesis. HOXA9 is expressed in EC (Endothelial Cells) and its expression is rapidly downregulated during EC activation by inflammatory signals like TNF-alpha (Tumor Necrosis Factor-Alpha) and LPS (lipopolysaccharide) . In humans,HOXA9 was found to be highly expressed and required in some subtypes of leukemia, particularly mixed lineage leukemia (MLL)-rearranged leukemia. The aberrant overexpression of HOXA9 is thought to be associated with poor survival of acute myeloid leukemia (AML) patients.
